Drug Insights

Navigating Health Information: How to Use Synapse to Search for Mirtazapine

9 February 2024
2 min read

Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain. These neurotransmitters are essential in regulating mood and emotions. By increasing their release, mirtazapine helps to alleviate the symptoms of major depressive disorder, which has been marketed under various trade names such as Razapina and Reflex. Developed by Merck Sharp & Dohme, this drug was first approved in the United States, China, Germany, and South Korea.This drug is available in tablet form and should be taken orally. However, caution should be taken when using this drug as it may cause side effects such as drowsiness, weight gain, and dry mouth. Despite the possible side effects, mirtazapine has shown efficacy in the treatment of depression. Click on the image below to begin the exploration journey of Mirtazapine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
Latest Hotspot
3 min read
Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
9 February 2024
Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
9 February 2024
Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway.
Read →
Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
Latest Hotspot
3 min read
Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
9 February 2024
Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.
Read →
The Synapse User's Toolkit: Tips for Searching Venlafaxine
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Venlafaxine
9 February 2024
Venlafaxine, an SNRI, targets SERT-5 and NET to regulate brain neurotransmitter balance.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.